Gene · 887
Papers2,046
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,046
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cholesterol-dependent dynamic changes in the conformation of the type 1 cholecystokinin receptor affect ligand binding and G protein coupling. | PLoS Biol | 2024 | 39083706 | PubTator, text mining | PubMed |
| Development and Validation of Novel Z-360-Based Macromolecules for the Active Targeting of CCK2-R. | Mol Pharm | 2024 | 38959127 | PubTator, text mining | PubMed |
| CCK Receptor Inhibition Reduces Pancreatic Tumor Fibrosis and Promotes Nanoparticle Delivery. | Biomedicines | 2024 | 38790986 | PubTator, text mining | PubMed |
| Cholecystokinin neurotransmission in the central nervous system: Insights into its role in health and disease. | Biofactors | 2024 | 38777339 | PubTator, text mining | PubMed |
| Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer. | Eur J Nucl Med Mol Imaging | 2024 | 38740575 | PubTator, text mining | PubMed |
| Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma. | BMC Med Genomics | 2024 | 38702698 | PubTator, text mining | PubMed |
| Cholecystokinin facilitates motor skill learning by modulating neuroplasticity in the motor cortex. | Elife | 2024 | 38700136 | PubTator, text mining | PubMed |
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial. | Clin Transl Med | 2024 | 38685486 | PubTator, text mining | PubMed |
| In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. | EJNMMI Res | 2024 | 38581480 | PubTator, text mining | PubMed |
| Biodistribution Assessment of a Novel 68Ga-Labeled Radiopharmaceutical in a Cancer Overexpressing CCK2R Mouse Model: Conventional and Radiomics Methods for Analysis. | Life (Basel) | 2024 | 38541733 | PubTator, text mining | PubMed |
| Acidity-Triggered "Sticky Spotlight": CCK2R-Targeted TME-Sensitive NIR Fluorescent Probes for Tumor Imaging In Vivo. | Bioconjug Chem | 2024 | 38514970 | PubTator, text mining | PubMed |
| Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs. | EJNMMI Res | 2024 | 38429609 | PubTator, text mining | PubMed |
| Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice. | Pharmaceuticals (Basel) | 2024 | 38399359 | PubTator, text mining | PubMed |
| Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023. | Theranostics | 2024 | 38250038 | PubTator, text mining | PubMed |
| Radioactive Molecules 2021-2022. | Molecules | 2024 | 38202848 | PubTator, text mining | PubMed |
| HOXC6: A promising biomarker linked to an immunoevasive microenvironment in colorectal cancer based on TCGA analysis and cohort validation. | Heliyon | 2024 | 38192826 | PubTator, text mining | PubMed |
| Multidirectional Planar Motion Transmission on a Single-Motor Actuated Robot via Microscopic Galumphing. | Adv Sci (Weinh) | 2024 | 38093662 | PubTator, text mining | PubMed |
| A novel telomere biology disease-associated gastritis identified through a whole exome sequencing-driven approach. | J Pathol Clin Res | 2024 | 37994393 | PubTator, text mining | PubMed |
| Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer. | J Nucl Med | 2024 | 37945383 | PubTator, text mining | PubMed |
| CCK2 Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [68Ga]Ga-DOTA-CCK-66. | J Nucl Med | 2024 | 37918864 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/887/papers?page=4